article thumbnail

Therapeutic effect and potential mechanism of Fufang Danshen dripping pills for stable coronary heart disease: a randomized controlled trial

Frontiers in Cardiovascular Medicine

Furthermore, we utilized mass spectrometry analysis, network pharmacology, and lipidomics to predict the potential mechanisms of FFDS in the treatment of SCHD.ResultsFollowing treatment, FFDS demonstrated significant improvements in serum triglyceride levels (P=0.013) and a reduction in the frequency of angina episodes (P=0.021).

article thumbnail

PCI for stable angina : Sham trials are welcome, but not OMT shaming trials !

Dr. S. Venkatesan MD

After a series of experiments in animals and peripheral vessels, he proved with a single patient N-1 study that effectively treated refractory LAD angina in a 38-year-old man in 1977. No one has questioned the efficacy of PCI for true angina with a critical lesion. Within a span of five to ten years, the concept spread globally.

Angina 52
article thumbnail

VahatiCor, Inc. Announces Treatment of First Patient with the A-FLUX Reducer System Innovation for Patients Suffering from Angina Due to Persistent Ischemic Heart Disease

DAIC

a med tech company dedicated to helping patients with persistent ischemic heart disease, has announced the treatment of the first patient with the A-FLUX Reducer System, a treatment for patients with angina or chest pain. Angina is often caused by reduced blood flow to the heart. VahatiCor, Inc.,

Angina 59
article thumbnail

Abstract 4122256: Health Status Outcomes of Nicorandil in Patients With Angina Pectoris: A Prospective, Multicenter, Registry-Based Study

Circulation

Circulation, Volume 150, Issue Suppl_1 , Page A4122256-A4122256, November 12, 2024. Approximately half of patients with CAD initially present with angina pectoris. The primary outcome was the Seattle Angina Questionnaire summary score (SAQ-SS) changes from baseline to 12 months.

Angina 40
article thumbnail

Abstract 4144084: Enhanced External Counterpulsation as a Novel Treatment for Heart Transplant Candidates with Ischemic Heart Failure with Reduced Ejection Fraction

Circulation

Circulation, Volume 150, Issue Suppl_1 , Page A4144084-A4144084, November 12, 2024. It is primarily indicated for refractory angina that is not amenable to PCI or CABG with the opinion of a cardiologist. It is primarily indicated for refractory angina that is not amenable to PCI or CABG with the opinion of a cardiologist.

article thumbnail

In Which Patients Will PCI Relieve Angina?

Circulation

Circulation, Ahead of Print.

Angina 45
article thumbnail

Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial

Circulation

Circulation, Ahead of Print. BACKGROUND:We investigated the usefulness of invasive coronary function testing to diagnose the cause of angina in patients with no obstructive coronary arteries.METHODS:Outpatients referred for coronary computed tomography angiography in 3 hospitals in the United Kingdom were prospectively screened.

Angina 40